GLP-1RAs治疗外周动脉疾病：朝着正确方向迈出的一大步

IF 27.7 1区生物学 Q1 CELL BIOLOGY

Cell metabolism Pub Date : 2025-06-03 DOI:10.1016/j.cmet.2025.05.001

Subodh Verma, David A. Hess

引用次数: 0

摘要

随着全球范围内T2D患病率的上升，外周动脉疾病（PAD）目前影响着全球2.3亿人。在最近的STRIDE试验中，Bonaca等人1证明，semaglutide改善了T2D患者的行走能力和血液动力学参数，并减缓了PAD的进展。这些结果揭示了GLP-1RAs具有意想不到的血管保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction

With the rising prevalence of T2D worldwide, peripheral artery disease (PAD) now affects >230 million individuals globally. In the recent STRIDE trial, Bonaca et al.¹ demonstrated that semaglutide improved walking capacity and hemodynamic parameters and slowed PAD progression in patients with T2D. These results reveal an unanticipated vasculoprotective benefit of GLP-1RAs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cell metabolism 生物-内分泌学与代谢

CiteScore

48.60

自引率

1.40%

发文量

173

审稿时长

2.5 months

期刊介绍： Cell Metabolism is a top research journal established in 2005 that focuses on publishing original and impactful papers in the field of metabolic research.It covers a wide range of topics including diabetes, obesity, cardiovascular biology, aging and stress responses, circadian biology, and many others. Cell Metabolism aims to contribute to the advancement of metabolic research by providing a platform for the publication and dissemination of high-quality research and thought-provoking articles.